目的 調(diào)查2017-2018年中國醫(yī)科大學(xué)附屬第一醫(yī)院氟比洛芬酯的應(yīng)用情況并對用藥合理性進(jìn)行評價(jià)。方法 利用中國醫(yī)科大學(xué)附屬第一醫(yī)院的電子病例管理系統(tǒng)，調(diào)取2017年1~6月、2018年1~6月應(yīng)用氟比洛芬酯注射液的全部住院病例，統(tǒng)計(jì)藥品使用數(shù)量及科室排名，并對抽樣調(diào)查的843例病例從適應(yīng)癥適宜性、藥品遴選適宜性、用法用量適宜性、療程適宜性及聯(lián)合用藥與相互作用適宜性幾個(gè)方面進(jìn)行合理性評價(jià)。結(jié)果 2018年氟比洛芬酯的消耗數(shù)量較2017年同期下降17%；843例病例中不合理率為61.0%，其中藥品遴選不適宜占32.3%，用法用量不適宜占17.1%，用藥療程不適宜占53.0%，聯(lián)合用藥或相互作用不適宜占1.9%。結(jié)論 中國醫(yī)科大學(xué)附屬第一醫(yī)院氟比洛芬酯的臨床應(yīng)用廣泛，不合理現(xiàn)象較為嚴(yán)重，應(yīng)加強(qiáng)管理，提高臨床合理用藥意識。

Objective To investigate the application of flurbiprofen axetil in the First Hospital of China Medical University from 2017 to 2018, and to evaluate the rationality of the medication use. Methods By using the electronic case management system of the First Hospital of China Medical University, all the inpatients who used Flurbiprofen Axetil Injection in January to June 2017 and January to June 2018 were selected, and the number of drugs used and the ranking of departments were counted. The 843 cases in the sampling survey were further studied from the aspects of suitability for indications, suitability for drug selection, suitability for usage and dosage, suitability for treatment course, and suitability for combination and interaction. Results The consumption of flurbiprofen axetil in 2018 decreased by 17% compared with the same period in 2017. In 843 cases, the unreasonable rate was 61.0%, in which 32.3% were unsuitable for drug selection, 17.1% were unsuitable for usage and dosage, 53.0% were unsuitable for treatment course, and 1.9% were unsuitable for combination or interaction. Conclusion Flurbiprofen axetil is widely used in clinic in the First Hospital of China Medical University, and its unreasonable phenomenon is serious. Medical institutions should strengthen the management and improve the consciousness of rational use of drugs in clinical practice.

R969.3